MyFinsight
Home
Blog
About
BIOLARGO, INC. (BLGO)
BIOLARGO, INC. (BLGO)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from clyra medical debt...
Stock option compensation expens...
Proceeds from sale of common sto...
Others
Negative Cash Flow Breakdown
Net income (loss), including por...
Contract liabilities
Equipment purchases
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss), including portion attributable to noncontrolling interest
-4,000
-3,405
-4,142
-7,244
Credit loss expense
-
-
-
3,849
Stock option compensation expense
722
699
1,014
844
Common stock issued for services
277
46
260
55
Bad debt expense
-
-
-
0
Ppp forgiveness
-
-
0
0
Credit loss expense
13
0
3,886
-
Amortization of debt discount
70
62
90
39
Amortization of right-of-use operating lease assets
52
49
42
51
Finance lease right -of-use asset amortization
-
-
113
-
Amortization of right-of-use finance lease asset
28
-23
-
18
Operating lease liabilities
-51
-47
-37
-50
Fair value of warrants issued for a fee and interest
-
-
0
-
Finance lease liability
25
24
23
22
Gain on investment in south korean joint venture
0
0
-23
0
Depreciation expense
33
34
33
34
Accounts receivable
7
115
-144
-410
Inventories
11
-18
-99
-35
Prepaid expenses and other assets
-14
-3
237
22
Accounts payable and accrued expenses-Entities Excluding Partially Owned Subsidiary
174
-135
321
-539
Deposits
-105
-1
89
10
Accounts payable and accrued expenses-Partially Owned Subsidiary
33
-168
372
-139
Contract liabilities
-273
39
280
0
Net cash used in operating activities
-3,056
-2,917
-1,590
-2,759
Equipment purchases
160
32
13
33
Clyra medical note receivable
-
-
0
-
Proceeds from note receivable
0
-
0
289
Net cash (used in) provided by investing activities
-160
-32
-13
256
Proceeds from biolargo warrant exercise-Clyra Medical Technologies
-
-
0
585
Proceeds from sale of common stock, net of offering costs
391
256
2,027
-
Proceeds from clyra medical note payable-Partially Owned Subsidiary
-
-
1,261
-
Proceeds from note payable
0
-
-
-
Proceeds from sale of common stock, net of offering costs-Beti Common Stock
-
-
425
0
Common stock issued for financing fee
0
85
-
-
Proceeds from biolargo warrant exercise-Biolargo Energy Technologies Inc BETI
-
-
0
-
Repayment of debt obligations
-24
8
6
18
Proceeds from beti unit offering-Biolargo Energy Technologies Inc BETI
25
362
-
100
Proceeds from clyra medical preferred series b-Clyra Medical Preferred Stock Series B
-
-
-
2,145
Proceeds from clyra medical debt obligations
1,000
1,134
-
0
Proceeds from sale of common stock, net of commissions
-
-
-
749
Repayment of clyra medical line of credit
134
-
-
-
Proceeds from debt obligation
-
-
-
50
Proceeds from clyra medical stock option exercise
5
-
0
0
Proceeds from sale of preferred stock in clyra medical-Partially Owned Subsidiary
-
-
2,145
-
Proceeds from clyra medical unit warrant offering
0
-
-
0
Proceeds from sale of common stock, net of offering costs-Clyra Medical Common Stock
0
0
150
0
Net cash provided by financing activities
1,279
3,190
952
3,570
Net effect of foreign currency translation
3
-2
-12
8
Net change in cash
-1,934
239
-663
1,075
Cash and cash equivalents at beginning of period
4,122
3,883
4,546
3,548
Cash and cash equivalents at end of period
2,188
4,122
3,883
4,546
Interest
342
-
-
-
Income taxes
0
-
-
-
Short-term lease payments not included in lease liabilities
17
-
-
-
Conversion of accounts receivable to a note receivable
0
-
-
-
Allocation of noncontrolling interest
-2,614
-
-
-
Fair value of clyra medical warrants issued as debt discount
353
-
-
-
Clyra medical dividend series a preferred stock
173
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from clyra
medical debt...
$1,000K
(-20.70%↓ Y/Y)
Proceeds from sale of
common stock, net of...
$391K
Proceeds from beti unit
offering-Biolargo Energy...
$25K
Proceeds from clyra
medical stock option...
$5K
Net cash provided by
financing activities
$1,279K
(-65.42%↓ Y/Y)
Net effect of
foreign currency...
$3K
(115.00%↑ Y/Y)
Canceled cashflow
$158K
Net change in cash
-$1,934K
(-2411.69%↓ Y/Y)
Canceled cashflow
$1,282K
Stock option
compensation expense
$722K
(-34.78%↓ Y/Y)
Common stock issued for
services
$277K
(-16.82%↓ Y/Y)
Accounts payable and
accrued...
$174K
(-64.05%↓ Y/Y)
Amortization of debt discount
$70K
(4.48%↑ Y/Y)
Amortization of right-of-use
operating lease assets
$52K
(-5.45%↓ Y/Y)
Accounts payable and
accrued...
$33K
(-77.08%↓ Y/Y)
Depreciation expense
$33K
(-57.69%↓ Y/Y)
Amortization of right-of-use
finance lease asset
$28K
(-15.15%↓ Y/Y)
Prepaid expenses and
other assets
-$14K
(57.58%↑ Y/Y)
Credit loss expense
$13K
Repayment of clyra medical
line of credit
$134K
Repayment of debt
obligations
-$24K
(-366.67%↓ Y/Y)
Net cash used in
operating activities
-$3,056K
(22.59%↑ Y/Y)
Canceled cashflow
$1,416K
Net cash (used in)
provided by investing...
-$160K
(-183.33%↓ Y/Y)
Net income (loss),
including portion...
-$4,000K
(-5.18%↓ Y/Y)
Contract liabilities
-$273K
Deposits
-$105K
(-54.41%↓ Y/Y)
Operating lease
liabilities
-$51K
(-2.00%↓ Y/Y)
Finance lease liability
$25K
(-41.86%↓ Y/Y)
Inventories
$11K
(-90.35%↓ Y/Y)
Accounts receivable
$7K
(-99.70%↓ Y/Y)
Equipment purchases
$160K
Buy us a coffee